Differences in anticoagulation strategy and outcome in atrial fibrillation patients with chronic kidney disease: a CODE‑AF registry study
10.1186/s42444-020-0011-2
- Author:
Yeon‑Jik CHOI
1
;
Jae‑Sun UHM
;
Tae‑Hoon KIM
;
Yeon‑Jik CHOI
;
Jae‑Sun UHM
;
Myung‑Jin CHA
;
Tae‑Hoon KIM
;
Jung Myung LEE
;
Junbeom PARK
;
Jin‑Kyu PARK
;
Ki‑Woon KANG
;
Jaemin SHIM
;
Jun KIM
;
Hyung Wook PARK
;
Eue‑Keun CHOI
;
Jin‑Bae KIM
;
Changsoo KIM
;
Young Soo LEE
;
Boyoung JOUNG
Author Information
1. Division of Cardiology, Department of Internal Medicine, Severance Car‑ diovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
- Publication Type:RESEARCH
- From:International Journal of Arrhythmia
2020;21(1):e3-
- CountryRepublic of Korea
- Language:0
-
Abstract:
Purpose:Dose reduction of non-vitamin K antagonist oral anticoagulants (NOACs) is indicated in patients with atrial fibrillation (AF) with renal impairment. This study investigated anticoagulation patterns and outcomes in patients with chronic kidney disease (CKD).
Materials and methods:In a prospective observational registry (CODE-AF), 3445 patients with non-valvular AF including 1129 with CKD (estimated glomerular filtration rate ≤ 60 mL min−1 1.73 m−2) were identified between June 1, 2016, and July 3, 2017.
Results:Compared with patients with no-CKD, patients with CKD more frequently had a high stroke risk (94.9% vs. 67.0%, p < 0.001) and higher NOAC usage rate (61.1% vs. 47.8%, p < 0.001). Among 718 patients with renal indication for dose reduction (RIDR), 7.5% were potentially overdosed. Among 2587 patients with no-RIDR, 79% were potentially underdosed. Compared with patients with no-RIDR, the underdose rates of dabigatran (0% vs. 88.6%, p = 0.001) and rivaroxaban (0% vs. 79.5%, p = 0.001) were lower in patients with RIDR. However, the underdose rate of apixaban was not different (62.5% vs. 53.9%, p = 0.089). The overdose rate of dabigatran (7.5% vs. 0%) and rivaroxaban (13.7% vs. 0%) was higher in RIDR than in no-RIDR patients. Stroke/transient ischemic attack was significantly higher in CKD patients (1.4 vs. 0.6 per 100 person-years, p = 0.045). Aspirin significantly increased minor bleeding in CKD patients compared with controls (p = 0.037).
Conclusion:CKD patients might have a high stroke risk and NOAC usage rate. The underdose rate of NOACs decreased in CKD patients, except for apixaban. Aspirin significantly increased minor bleeding in CKD patients.
